Prismic Pharmaceuticals

Nephrology - Medical Foods

Prismic has two lead products derived from Palmitoylethanolamide in development for chronic kidney disease (CKD).


A proprietary formulation of micronized Palmitoylethanolamide, in a 400 mg tablet, being developed as a Medical Food for reduction of inflammation and pain (of any etiology) in patients with CKD.

The addressable market for NEFROGESIC(TM) is estimated at 2.3 million diagnosed patients in stages 3, 4, and 5 of CKD.


A proprietary formulation of micronized Palmitoylethanolamide in combination with Silymarin, in a tablet form containing 200 mg of Palmitoylethanolamide and 140 mg of Silymarin.  It is under development for the reduction of albuminuria and proteinuria (albumin/protein in the urine) which are key markers associated with the progression of CKD.

The addressable market for NEFROSIL(TM) is estimated at 1.4 million diagnosed patients in stages 3 and 4 of CKD who have albuminuria/proteinuria.

CNS Disorder - Medical Foods


Prismic's pharmaceutically active ingredient, ultra-pure, EPA-based Omega-3, is derived from the assets Prismic acquired through its purchase of Scarista Ltd. in 2011.  Prismic's lead CNS product, NEUREPA(R), is a unique patented formulation of an Omega-3 triglyceride concentrate that is 92% EPA.  It was developed and specifically formulated to address the Omega-3 deficiency in patients suffering from depression and bipolar disorder (the depressive phase).

There are 211 million prescriptions written each year for anti-depressants in the United States.  Of these, the addressable market for NEUREPA(R) is estimated at 74.4 million prescriptions.  This is based on the number of prescriptions written by high prescribing (decile 6-10) doctors in 3 leading specialties, namely Primary Care (44.9 million), Psychiatrists (21.1 million), and Obstetricians and Gynecologists (8.4 million).

Additionally, line extensions of NEUREPA(R) are being formulated for other related patient populations and conditions, and also as part of the company's life cycle management based on the company's existing IP portfolio.  

NEUREPA (R)  Information

NEUREPA® (Omega-3 triglyceride) is a prescription medical food intended for the clinical dietary management of:

  1. Depression
  2. Bipolar Disorder

The ONLY Rx Omega-3 formulation that:

  1. Provides 92% EPA per gram of oil
  2. Is in the Triglyceride form allowing for increased bioavailability
  3. Has been developed specifically for Psychiatrists, Obstetricians, and Gynaecologists, and their patients
  4. Is available only by prescription and under the ongoing supervision of a medical practitioner   

Medical Foods